Alcon (NYSE:ALC) and RxSight (Nasdaq:RXST) announced that they entered into a non-exclusive intraocular lens (IOL) ...

ALC is developing adjustable presbyopia-correcting lenses that pair advanced optics with post-surgery light adjustment.

Alcon's $200M RxSight partnership aims to recapture IOL market share with adjustable presbyopic lenses. RxSight gets 30% ...

The companies will combine their expertise to develop a ‘tuneable’ presbyopia-correcting intraocular lens (PCIOL) for ...

Alcon and RxSight, Inc have announced a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting ...

Alcon and RxSight announced a nonexclusive collaboration to develop a light-adjustable presbyopia-correcting IOL, according ...

Despite near-term headwinds, RxSight has long-term upside from the Alcon royalty partnership, stronger margins and discounted ...

A new Alcon-sponsored survey conducted by Wakefield Research uncovered a gap between parental recognition of the role of ...

Over the last several years, the RxSight team has been developing proprietary hybrid IOL materials for next-generation light adjustable technology that can support a full suite of adjustable lenses ...

GENEVA--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, announced today the launch of DAILIES TOTAL1 ® for Astigmatism, the first and ...

RxSight, Inc. (NASDAQ: RXST) today announced select preliminary financial results for the second quarter of 2026 and updates to its standalone product pipeline, following the announcement of the ...

SEATTLE — IOL makers have introduced lens-specific injector systems for their most popular models, allowing more cataract surgeons access to the ease of using shooters. According to Andy Stapars, ...